SEARCH

SEARCH BY CITATION

References

  • Ansell, S.M., Kyle, R.A., Reeder, C.B., Fonseca, R., Mikhael, J.R., Morice, W.G., Bergsagel, P.L., Buadi, F.K., Colgan, J.P., Dingli, D., Dispenzieri, A., Greipp, P.R., Habermann, T.M., Hayman, S.R., Inwards, D.J., Johnston, P.B., Kumar, S.K., Lacy, M.Q., Lust, J.A., Markovic, S.N., Micallef, I.N., Nowakowski, G.S., Porrata, L.F., Roy, V., Russell, S.J., Short, K.E., Stewart, A.K., Thompson, C.A., Witzig, T.E., Zeldenrust, S.R., Dalton, R.J., Rajkumar, S.V. & Gertz, M.A. (2010) Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clinic Proceedings, 85, 824833.
  • Bachanova, V. & Burns, L.J. (2012) Hematopoietic cell transplantation for Waldenström macroglobulinemia. Bone Marrow Transplantation, 47, 330336.
  • Berentsen, S. (2007) Rituximab for the treatment of autoimmune cytopenias. Haematologica, 92, 15891596.
  • Berentsen, S., Randen, U., Vagan, A.M., Hjorth-Hansen, H., Vik, A., Dalgaard, J., Jacobsen, E.M., Thoresen, A.S., Beiske, K. & Tjonnfjord, G.E. (2010) High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood, 116, 31803184.
  • Buske, C., Hoster, E., Dreyling, M., Eimermacher, H., Wandt, H., Metzner, B., Fuchs, R., Bittenbring, J., Woermann, B., Hohloch, K., Hess, G., Ludwig, W.D., Schimke, J., Schmitz, S., Kneba, M., Reiser, M., Graeven, U., Klapper, W., Unterhalt, M., Hiddemann, W. & German Low-Grade Lymphoma Study Group. (2009) The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia, 23, 153161.
  • Chang, H., Qi, C., Trieu, Y., Jiang, A., Young, K.H., Chesney, A., Jani, P., Wang, C., Reece, D. & Chen, C. (2009) Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study. Clinical Lymphoma & Myeloma, 9, 3638.
  • Chen, C., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W. & Eisenhauer, E. (2009) Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. Clinical Lymphoma & Myeloma, 9, 7476.
  • Cohen, A.D., Zhou, P., Xiao, Q., Fleisher, M., Kalakonda, N., Akhurst, T., Chitale, D.A., Moscowitz, C., Dhodapkar, M.V., Teruya-Feldstein, J., Filippa, D. & Comenzo, R.L. (2004) Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. British Journal of Haematology, 124, 309314.
  • Dhodapkar, M.V., Hoering, A., Gertz, M.A., Rivkin, S., Szymonifka, J., Crowley, J. & Barlogie, B. (2009) Long-term survival in Waldenström macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood, 113, 793796.
  • Dimopoulos, M.A., Kantarjian, H., Estey, E., O'Brien, S., Delasalle, K., Keating, M.J., Freireich, E.J. & Alexanian, R. (1993) Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Annals of Internal Medicine, 118, 195198.
  • Dimopoulos, M.A., Anagnostopoulos, A., Kyrtsonis, M.C., Zervas, K., Tsatalas, C., Kokkinis, G., Repoussis, P., Symeonidis, A., Delimpasi, S., Katodritou, E., Vervessou, E., Michali, E., Pouli, A., Gika, D., Vassou, A., Terpos, E., Anagnostopoulos, N., Economopoulos, T. & Pangalis, G. (2007) Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. Journal of Clinical Oncology, 25, 33443349.
  • Elsawa, S.F., Novak, A.J., Ziesmer, S.C., Almada, L.L., Hodge, L.S., Grote, D.M., Witzig, T.E., Fernandez-Zapico, M.E. & Ansell, S.M. (2011) Comprehensive analysis of tumor microenvironment cytokines in Waldenström macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood, 118, 55405549.
  • Figueroa, J.J., Bosch, E.P., Dyck, P.J., Singer, W., Vrana, J.A., Theis, J.D., Dogan, A. & Klein, C.J. (2012) Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder. Journal of the Peripheral Nervous System, 17, 182190.
  • Foran, J.M., Rohatiner, A.Z., Coiffier, B., Barbui, T., Johnson, S.A., Hiddemann, W., Radford, J.A., Norton, A.J., Tollerfield, S.M., Wilson, M.P. & Lister, T.A. (1999) Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. Journal of Clinical Oncology, 17, 546553.
  • Gachard, N., Parrens, M., Soubeyran, I., Petit, B., Marfak, A., Rizzo, D., Devesa, M., Delage-Corre, M., Coste, V., Laforet, M.P., de Mascarel, A., Merlio, J.P., Bouabdhalla, K., Milpied, N., Soubeyran, P., Schmitt, A., Bordessoule, D., Cogne, M. & Feuillard, J. (2013) IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia, 27, 183189.
  • Gertz, M.A. (2012) Baby, it's cold outside!. Blood, 119, 59435944.
  • Gertz, M.A., Kyle, R.A. & Noel, P. (1993) Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. Journal of Clinical Oncology, 11, 914920.
  • Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. & Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukemia & Lymphoma, 45, 20472055.
  • Gertz, M.A., Abonour, R., Heffner, L.T., Greipp, P.R., Uno, H. & Rajkumar, S.V. (2009) Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. British Journal of Haematology, 147, 677680, Epub 2009 Sep 14.
  • Gertz, M.A., Buadi, F.K. & Hayman, S.R. (2011) IgM amyloidosis: clinical features in therapeutic outcomes. Clinical Lymphoma, Myeloma & Leukemia, 11, 146148.
  • Ghobrial, I.M. (2012) Are you sure this is Waldenstrom macroglobulinemia? American Society of Hematology Education Book, 2012, 586594.
  • Ghobrial, I.M., Fonseca, R., Greipp, P.R., Blood, E., Rue, M., Vesole, D.H., Gertz, M.A. & Eastern Cooperative Oncology Group. (2004) Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer, 101, 25932598.
  • Ghobrial, I.M., Xie, W., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Poon, T., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E. & Matous, J. (2010a) Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American Journal of Hematology, 85, 670674.
  • Ghobrial, I.M., Hong, F., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E. & Matous, J. (2010b) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. Journal of Clinical Oncology, 28, 14221428.
  • Ghobrial, I.M., Gertz, M., Laplant, B., Camoriano, J., Hayman, S., Lacy, M., Chuma, S., Harris, B., Leduc, R., Rourke, M., Ansell, S.M., Deangelo, D., Dispenzieri, A., Bergsagel, L., Reeder, C., Anderson, K.C., Richardson, P.G., Treon, S.P. & Witzig, T.E. (2010c) Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. Journal of Clinical Oncology, 28, 14081414.
  • Ghobrial, I.M., Roccaro, A., Hong, F., Weller, E., Rubin, N., Leduc, R., Rourke, M., Chuma, S., Sacco, A., Jia, X., Azab, F., Azab, A.K., Rodig, S., Warren, D., Harris, B., Varticovski, L., Sportelli, P., Leleu, X., Anderson, K.C. & Richardson, P.G. (2010d) Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clinical Cancer Research, 16, 10331041.
  • Ghobrial, I.M., Poon, T., Rourke, M., Chuma, S., Kunsman, J., Banwait, R., Sam, A., Warren, D., Anderson, K., Richardson, P., Treon, S. & Matous, J. (2010e) Phase II trial of single agent panobinostat (LBH589) in relapsed or relapsed/refractory Waldenström macroglobulinemia abstract. Blood (ASH Annual Meeting Abstracts), 116, 3952.
  • Ghobrial, I.M., Moreau, P., Harris, B., Poon, T., Jourdan, E., Maisonneuve, H., Benhadji, K.A., Hossain, A.M., Nguyen, T.S., Wooldridge, J.E. & Leblond, V. (2012) A multicenter phase II study of single-agent enzastaurin in previously treated Waldenström macroglobulinemia. Clinical Cancer Research, 18, 50435050.
  • Hodge, L.S. & Ansell, S.M. (2011) Jak/Stat pathway in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 112114.
  • Hultcrantz, M.L., Pfeiffer, R.M., Bjorkholm, M., Goldin, L., Turesson, I., Schulman, S., Landgren, O. & Kristinsson, S.Y. (2012) Elevated risk of venous but not arterial thrombosis in Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts), 120, 1603.
  • Hunter, Z.R., Manning, R.J., Hanzis, C., Ciccarelli, B.T., Ioakimidis, L., Patterson, C.J., Lewicki, M.C., Tseng, H., Gong, P., Liu, X., Zhou, Y., Yang, G., Sun, J., Xu, L., Sheehy, P., Morra, M. & Treon, S.P. (2010) IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica, 95, 470475.
  • Issa, G.C., Leblebjian, H., Roccaro, A.M. & Ghobrial, I.M. (2011a) New insights into the pathogenesis and treatment of Waldenström macroglobulinemia. Current Opinion in Hematology, 18, 260265.
  • Issa, G.C., Ghobrial, I.M. & Roccaro, A.M. (2011b) Novel agents in Waldenström macroglobulinemia. Clinical Investigation (London), 1, 815824.
  • Kastritis, E., Kyrtsonis, M.C., Hadjiharissi, E., Symeonidis, A., Michalis, E., Repoussis, P., Tsatalas, C., Michael, M., Sioni, A., Kartasis, Z., Stefanoudaki, E., Voulgarelis, M., Delimpasi, S., Gavriatopoulou, M., Koulieris, E., Gika, D., Zomas, A., Roussou, P., Anagnostopoulos, N., Economopoulos, T., Terpos, E., Zervas, K., Dimopoulos, M.A. & Greek Myeloma Study Group. (2010) Validation of the International Prognostic Scoring System (IPSS) for Waldenström's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leukemia Research, 34, 13401343.
  • Klein, C.J., Moon, J.S., Mauermann, M.L., Zeldenrust, S.R., Wu, Y., Dispenzieri, A. & Dyck, P.J. (2011) The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. The Canadian Journal of Neurological Sciences, 38, 289295.
  • Kristinsson, S.Y., Bjorkholm, M., Goldin, L.R., McMaster, M.L., Turesson, I. & Landgren, O. (2008) Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. Blood, 112, 30523056.
  • Kyle, R.A., Greipp, P.R., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (2000) Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. British Journal of Haematology, 108, 737742.
  • Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Remstein, E.D., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. 3rd (2003a) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood, 102, 37593764.
  • Kyle, R.A., Treon, S.P., Alexanian, R., Barlogie, B., Bjorkholm, M., Dhodapkar, M., Lister, T.A., Merlini, G., Morel, P., Stone, M., Branagan, A.R. & Leblond, V. (2003b) Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Seminars in Oncology, 30, 116120.
  • Kyriakou, C., Canals, C., Sibon, D., Cahn, J.Y., Kazmi, M., Arcese, W., Kolbe, K., Gorin, N.C., Thomson, K., Milpied, N., Niederwieser, D., Indrak, K., Corradini, P., Sureda, A. & Schmitz, N. (2010) High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 28, 22272232.
  • Landgren, O. & Staudt, L. (2012) MYD88 L265P somatic mutation in IgM MGUS. New England Journal of Medicine, 367, 22552256.
  • Laszlo, D., Andreola, G., Rigacci, L., Fabbri, A., Rabascio, C., Mancuso, P., Pruneri, G., Radice, D., Pinto, A., Frigeri, F., Calabrese, L., Billio, A., Bertolini, F. & Martinelli, G. (2010) Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenström macroglobulinemia: clinical and biologic results of a phase II multicenter study. Journal of Clinical Oncology, 28, 22332238.
  • Leblond, V., Johnson, S., Chevret, S., Copplestone, A., Rule, S., Tournilhac, O., Seymour, J.F., Patmore, R.D., Wright, D., Morel, P., Dilhuydy, M.S., Willoughby, S., Dartigeas, C., Malphettes, M., Royer, B., Ewings, M., Pratt, G., Lejeune, J., Nguyen-Khac, F., Choquet, S. & Owen, R.G. (2013) Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. Journal of Clinical Oncology, 31, 301307.
  • Leleu, X., Soumerai, J., Roccaro, A., Hatjiharissi, E., Hunter, Z.R., Manning, R., Ciccarelli, B.T., Sacco, A., Ioakimidis, L., Adamia, S., Moreau, A.S., Patterson, C.J., Ghobrial, I.M. & Treon, S.P. (2009) Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. Journal of Clinical Oncology, 27, 250255.
  • Lopate, G., Pestronk, A., Al-Lozi, M., Lynch, T., Florence, J., Miller, T., Levine, T., Rampy, T., Beson, B. & Ramneantu, I. (2006) Peripheral neuropathy in an outpatient cohort of patients with Sjogren's syndrome. Muscle and Nerve, 33, 672676.
  • Ly, K.I., Hochberg, E.P. & Hochberg, F.H. 2012. The Bing-Neel Syndrome: clinical observations on nine new cases and the literature. Paper presented at: International Workshops on Waldenström's Macroglobulinemia. 7th International Workshop on Waldenström's Macroglobulinemia and Symposium on Advances in Multiple Myeloma; 2012 Aug 23–26; Newport, RI.
  • Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M.A., Dhodapkar, M.V., McCoy, J., Crowley, J., Ocio, E.M., Garcia-Sanz, R., Treon, S.P., Leblond, V., Kyle, R.A., Barlogie, B. & Merlini, G. (2009) International prognostic scoring system for Waldenström macroglobulinemia. Blood, 113, 41634170.
  • Nguyen-Khac, F., Lambert, J., Chapiro, E., Grelier, A., Mould, S., Barin, C., Daudignon, A., Gachard, N., Struski, S., Henry, C., Penther, D., Mossafa, H., Andrieux, J., Eclache, V., Bilhou-Nabera, C., Luquet, I., Terre, C., Baranger, L., Mugneret, F., Chiesa, J., Mozziconacci, M.J., Callet-Bauchu, E., Veronese, L., Blons, H., Owen, R., Lejeune, J., Chevret, S., Merle-Beral, H. & Leblond, V. (2012) Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström macroglobulinemia. Haematologica, 98, 649654.
  • Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Seminars in Oncology, 30, 110115.
  • Owen, R.G., Kyle, R.A., Stone, M.J., Rawstron, A.C., Leblond, V., Merlini, G., Garcia-Sanz, R., Ocio, E.M., Morra, E., Morel, P., Anderson, K.C., Patterson, C.J., Munshi, N.C., Tedeschi, A., Joshua, D.E., Kastritis, E., Terpos, E., Ghobrial, I.M., Leleu, X., Gertz, M.A., Ansell, S.M., Morice, W.G., Kimby, E. & Treon, S.P. (2013) Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. British Journal of Haematology, 160, 171176.
  • Palladini, G., Russo, P., Bosoni, T., Sarais, G., Lavatelli, F., Foli, A., Bragotti, L.Z., Perfetti, V., Obici, L., Bergesio, F., Albertini, R., Moratti, R. & Merlini, G. (2009) AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clinical Lymphoma & Myeloma, 9, 8083.
  • Rummel, M.J., Lerchenmuller, C., Greil, R., Gorner, M., Hensel, M., Engel, E., Jaeger, U., Breuer, F., Hertenstein, B., Prummer, O., Buske, C., Barth, J., Burchardt, A.C. & Brugger, W. (2012) Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenström's macroglobulinemia: results from a prospective, randomized, multicenter study (StiL NHL 7–2008–MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214). Blood(ASH Annual Meeting Abstracts), 120, 2739.
  • Stone, M.J. (2011) Pathogenesis and morbidity of autoantibody syndromes in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 157159.
  • Stone, M.J. & Bogen, S.A. (2012) Evidence-based focused review of management of hyperviscosity syndrome. Blood, 119, 22052208.
  • Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds). (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
  • Tedeschi, A., Benevolo, G., Varettoni, M., Battista, M.L., Zinzani, P.L., Visco, C., Meneghini, V., Pioltelli, P., Sacchi, S., Ricci, F., Nichelatti, M., Zaja, F., Lazzarino, M., Vitolo, U. & Morra, E. (2012) Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer, 118, 434443.
  • Telio, D., Bailey, D., Chen, C., Crump, M., Reece, D. & Kukreti, V. (2010) Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature. American Journal of Hematology, 85, 805808.
  • Treon, S.P. (2009) How I treat Waldenström macroglobulinemia. Blood, 114, 23752385.
  • Treon, S.P., Hunter, Z.R., Aggarwal, A., Ewen, E.P., Masota, S., Lee, C., Santos, D.D., Hatjiharissi, E., Xu, L., Leleu, X., Tournilhac, O., Patterson, C.J., Manning, R., Branagan, A.R. & Morton, C.C. (2006) Characterization of familial Waldenström's macroglobulinemia. Annals of Oncology, 17, 488494.
  • Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Briccetti, F.M., Pasmantier, M., Zimbler, H., Cooper, R.B., Moore, M., Hill, J. 2nd, Rauch, A., Garbo, L., Chu, L., Chua, C., Nantel, S.H., Lovett, D.R., Boedeker, H., Sonneborn, H., Howard, J., Musto, P., Ciccarelli, B.T., Hatjiharissi, E. & Anderson, K.C. (2008) Thalidomide and rituximab in Waldenström macroglobulinemia. Blood, 112, 44524457.
  • Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Chu, L., Musto, P., Baron, A.D., Nunnink, J.C., Kash, J.J., Terjanian, T.O., Hyman, P.M., Nawfel, E.L., Sharon, D.J., Munshi, N.C. & Anderson, K.C. (2009a) Lenalidomide and rituximab in Waldenström's macroglobulinemia. Clinical Cancer Research, 15, 355360.
  • Treon, S.P., Branagan, A.R., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Turnbull, B., Wasi, P., Emmanouilides, C., Frankel, S.R., Lister, A., Morel, P., Matous, J., Gregory, S.A. & Kimby, E. (2009b) Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood, 113, 36733678.
  • Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J. 2nd, Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L. & Ghobrial, I.M. (2009c) Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. Journal of Clinical Oncology, 27, 38303835.
  • Treon, S.P., Yang, G., Hanzis, C., Ioakimidis, L., Verselis, S.J., Fox, E.A., Xu, L., Hunter, Z.R., Tseng, H., Manning, R.J., Patterson, C.J., Sheehy, P. & Turnbull, B. (2011a) Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenström macroglobulinaemia. British Journal of Haematology, 154, 223228.
  • Treon, S.P., Hanzis, C., Manning, R.J., Ioakimidis, L., Patterson, C.J., Hunter, Z.R., Sheehy, P. & Turnbull, B. (2011b) Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenström macroglobulinaemia who respond to a rituximab-containing regimen. British Journal of Haematology, 154, 357362.
  • Treon, S.P., Soumerai, J.D., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Kahl, B. & Boxer, M. (2011c) Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood, 118, 276281.
  • Treon, S.P., Hanzis, C., Tripsas, C., Ioakimidis, L., Patterson, C.J., Manning, R.J. & Sheehy, P. (2011d) Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 133135.
  • Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R.J., Patterson, C.J., Tripsas, C., Arcaini, L., Pinkus, G.S., Rodig, S.J., Sohani, A.R., Harris, N.L., Laramie, J.M., Skifter, D.A., Lincoln, S.E. & Hunter, Z.R. (2012) MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. New England Journal of Medicine, 367, 826833.
  • Usmani, S., Sexton, R., Crowley, J. & Barlogie, B. (2011) Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 139142.
  • Varettoni, M., Tedeschi, A., Arcaini, L., Pascutto, C., Vismara, E., Orlandi, E., Ricci, F., Corso, A., Greco, A., Mangiacavalli, S., Lazzarino, M. & Morra, E. (2012) Risk of second cancers in Waldenström macroglobulinemia. Annals of Oncology, 23, 411415.
  • Wang, H., Chen, Y., Li, F., Delasalle, K., Wang, J., Alexanian, R., Kwak, L., Rustveld, L., Du, X.L. & Wang, M. (2012) Temporal and geographic variations of Waldenström macroglobulinemia incidence: a large population-based study. Cancer, 118, 37933800.
  • Wechalekar, A.D., Lachmann, H.J., Goodman, H.J., Bradwell, A., Hawkins, P.N. & Gillmore, J.D. (2008) AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112, 40094016.
  • Xu, L., Hunter, Z.R., Yang, G., Zhou, Y., Cao, Y., Liu, X., Morra, E., Trojani, A., Greco, A., Arcaini, L., Varettoni, M., Brown, J.R., Tai, Y.T., Anderson, K.C., Munshi, N.C., Patterson, C.J., Manning, R., Tripsas, C., Lindeman, N.I. & Treon, S.P. (2013) MYD88 L265P in Waldenström's macroglobulinemia, IgM monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific PCR. Blood, 121, 20512058.